Skip Navigation


Cardiovascular Research Advance Access originally published online on December 4, 2007
Cardiovascular Research 2008 77(4):659-666; doi:10.1093/cvr/cvm084
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
77/4/659    most recent
cvm084v3
cvm084v2
cvm084v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morimoto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morimoto, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Sarcomeric proteins and inherited cardiomyopathies

Sachio Morimoto*

Laboratory of Clinical Pharmacology, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

* Corresponding author. Tel: +81 92 642 6081; fax: +81 92 642 6084. E-mail address: morimoto{at}med.kyushu-u.ac.jp

Over the last two decades, a large number of mutations have been identified in sarcomeric proteins as a cause of hypertrophic, dilated or restrictive cardiomyopathy. Functional analyses of mutant proteins in vitro have revealed several important functional changes in sarcomeric proteins that might be primarily involved in the pathogenesis of each cardiomyopathy. Creation of transgenic or knock-in animals expressing mutant proteins in their hearts confirmed that these mutations in genes for sarcomeric proteins induced distinct types of cardiomyopathies and provided useful animal models to explore the molecular pathogenic mechanisms and potential therapeutics of cardiomyopathy in vivo. In this review, I discuss the functional consequences of mutations in different sarcomeric proteins found in hypertrophic, dilated, and restrictive cardiomyopathies in conjunction with their effects on cardiac structure and function in vivo and their possible molecular and cellular mechanisms, which underlie the pathogenesis of these inherited cardiomyopathies.

KEYWORDS Sarcomere; Gene mutation; Hypertrophic cardiomyopathy; Dilated cardiomyopathy; Restricted cardiomyopathy


Time for primary review: 17 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, and T. Sasaguri
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation
Cardiovasc Res, June 17, 2009; (2009) cvp168v2.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Z. Armel and L. A. Leinwand
Mutations in the {beta}-myosin rod cause myosin storage myopathy via multiple mechanisms
PNAS, April 14, 2009; 106(15): 6291 - 6296.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. S. Willis, J. C. Schisler, A. L. Portbury, and C. Patterson
Build it up-Tear it down: protein quality control in the cardiac sarcomere
Cardiovasc Res, February 15, 2009; 81(3): 439 - 448.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. J. Solaro and P. P. de Tombe
Review focus series: sarcomeric proteins as key elements in integrated control of cardiac function
Cardiovasc Res, March 1, 2008; 77(4): 616 - 618.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.